Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 29, 2024

Kivu Bioscience secures $92m in Series A funding for ADC development

Kivu Bioscience has completed a $92m Series A funding round, spearheaded by Novo Holdings to propel the development of next-generation antibody-drug conjugates (ADCs).

The funds will be channelled towards advancing Kivu’s multiple oncology programmes into clinical trials. Credit: JOSHUA COLEMAN on Unsplash.